本文来源:时代财经 作者:李傲华双抗赛道日渐升温。11月18日,橙帆医药宣布与Avenzo Therapeutics达成一项全球战略合作协议,橙帆医药将授予Avenzo在全球范围内(不包括大中华区)开发、生产和商业化Nectin4/TROP2双特异性抗体偶联药物(ADC),同时保留在大中华区的相关权益。根据约定,橙帆医药可以获得5000万美元的首付款及近期里程碑付款,以及后续最高达7.5亿美元的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.